Work

Insights Into Vepdegestrant (ARV‐471): The First‐in‐Class Estrogen Receptor Proteolysis‐Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer

Year: 2026

Type: article

Source: ChemMedChem

DOI: 10.1002/cmdc.202501111

Authors: Chao Tang, Bin Tian, Bingxing Zhang, Yunfei Zhang, Changhua Ke, Mengxin Chen, Meiyan Wei, Wen Wang, Xintao Deng, Qiannan Zhang, Mengzhou Wang, Juan Xia, Meiling He, Chengyuan Liang, Lei Tian

Institutions: Shaanxi University of Science and Technology, Guangdong Medical College, Central People's Hospital of Zhanjiang

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Shaanxi Administration of Traditional Chinese Medicine, National Natural Science Foundation of China

Awards: G1226090532, G4131783428, G5307845065, G8587803044

OpenAlex ID: W7140123861

FWCI: 22.29

Cites: 64

Cited by: 12

Related to: